FSGS小鼠模型中YAP与足细胞凋亡的相关性及其激动剂的保护作用

doi:10.3969/j.issn.1672-8467.2023.04.001

PDF(2782 KB)

复旦学报(医学版) ›› 2023, Vol. 50 ›› Issue (04) : 475-486. DOI: 10.3969/j.issn.1672-8467.2023.04.001

论著

FSGS小鼠模型中YAP与足细胞凋亡的相关性及其激动剂的保护作用

曾明垚¹, 陈泓儒¹, 齐晨阳¹, 赵仲华¹, 李芳^2,3, 张志刚^1,3, 吴慧娟^1,3

作者信息 +

Correlation between YAP and podocyte apoptosis and the protective effect of YAP agonist in FSGS mice model

ZENG Ming-yao¹, CHEN Hong-ru¹, QI Chen-yang¹, ZHAO Zhong-hua¹, LI Fang^2,3, ZHANG Zhi-gang^1,3, WU Hui-juan^1,3

Author information +

文章历史 +

摘要

目的探究YAP与局灶节段性肾小球硬化症（focal segmental glomerulosclerosis，FSGS）中足细胞凋亡的相关性及其激动剂的作用。方法收取复旦大学基础医学院病理学系肾病研究组人FSGS肾穿标本，使用阿霉素刺激构建FSGS小鼠模型和体外足细胞损伤模型，并联合YAP激动剂1-油酰基溶血磷脂酸（1-Oleoyl lysophosphatidic acid，LPA）处理上述体内外模型，使用免疫组化、免疫荧光双染、Western blot及Hoechst 33258染色检测足细胞凋亡和足细胞中YAP表达的相关性；使用LPA处理转染YAP siRNA的足细胞系后，检测足细胞中YAP表达和凋亡的变化。结果在人FSGS、FSGS小鼠模型和体外阿霉素诱导足细胞损伤模型中足细胞凋亡越多，YAP出核越多；LPA处理可以改善FSGS小鼠模型的肾脏形态（t=17.68，P<0.000 1）和肾功能（血尿素氮：t=4.576，P=0.010 2；尿白蛋白/肌酐：t=2.51，P=0.045 6），减少足细胞中p-YAP（S127）的表达，促进YAP入核，减少阿霉素诱导的足细胞凋亡（Cleaved Caspase-3的表达及Hoechst 33258染色结果均为P<0.001）；敲减足细胞中YAP后，YAP的总蛋白和磷酸化水平均降低，足细胞凋亡增加，LPA处理减少了p-YAP（S127）的表达，促进YAP入核，减少YAP敲减所致的足细胞凋亡（Cleaved Caspase-3的表达及Hoechst 33258染色结果均为P<0.000 1）。结论 FSGS模型中活化YAP减少及YAP出核，足细胞凋亡增多；LPA能够通过抑制YAP在Ser127位点的磷酸化，促进足细胞中YAP的入核，减少细胞凋亡，延缓FSGS的疾病进程。

Abstract

Objective To investigate the correlation between YAP and podocytes apoptosis in focal segmental glomerulosclerosis （FSGS） and the role of YAP activator on the podocytes apoptosis.Methods The renal biopsy specimens of human FSGS were collected from the Nephrology Research Group of the Department of Pathology， School of Basic Medical Sciences， Fudan University. Adriamycin-induced FSGS mice model and Adriamycin-induced podocytes injury model in vitro were generated， and the above in vivo or in vitro model were treated in combination with YAP activator 1-Oleoyl lysophosphatidic acid （LPA）. Immunohistochemistry （IHC） or double immunofluorescence staining， Western blot and Hoechst 33258 staining were used to examine the correlation between podocytes apoptosis and the expression of YAP in podocytes. Podocytes transfected with YAP siRNA were treated with LPA， and then YAP expression and podocytes apoptosis were examined.Results The more apoptotic podocytes， the more nuclear exclusion of YAP in FSGS were observed either in vivo or in vitro. YAP activator LPA improved glomerular morphology （t=17.68，P<0.000 1） and renal function（BUN：t=4.576，P=0.010 2；UACR：t=2.51，P=0.045 6） of Adriamycin-induced FSGS mice model， reduced the expression of p-YAP （S127）， increased YAP nuclear entry and decreased podocyte apoptosis （P<0.001 for both expression of Cleaved Caspase-3 and Hoechst 33258 staining） induced by Adriamycin both in vivo and in vitro. RNA interference of YAP decreased both total and phosphorylated YAP expression， and increased podocytes apoptosis. LPA treatment decreased the expression of p-YAP （S127）， promoted YAP nuclear localization and decreased the podocytes apoptosis （P<0.000 1 for both expression of Cleaved Caspase-3 and Hoechst 33258 staining） induced by YAP interference.Conclusion There are decrease in YAP activation， nuclear exclusion of YAP， and increased podocytes apoptosis in FSGS model. LPA can inhibit the phosphorylation of YAP at Ser127， promote its nuclear translocation， thus to protect podocytes from apoptosis to ameliorate the progression of FSGS.

导出引用

曾明垚, 陈泓儒, 齐晨阳, 赵仲华, 李芳, 张志刚, 吴慧娟. FSGS小鼠模型中YAP与足细胞凋亡的相关性及其激动剂的保护作用[J]. 复旦学报(医学版), 2023, 50(04): 475-486 https://doi.org/10.3969/j.issn.1672-8467.2023.04.001

ZENG Ming-yao, CHEN Hong-ru, QI Chen-yang, ZHAO Zhong-hua, LI Fang, ZHANG Zhi-gang, WU Hui-juan. Correlation between YAP and podocyte apoptosis and the protective effect of YAP agonist in FSGS mice model[J]. Fudan University Journal of Medical Sciences, 2023, 50(04): 475-486 https://doi.org/10.3969/j.issn.1672-8467.2023.04.001

中图分类号： R692.3

参考文献

[1] FOGO AB.Causes and pathogenesis of focal segmental glomerulosclerosis[J].Nat Rev Nephrol,2015,11(2):76-87.
[2] KITIYAKARA C,KOPP JB,EGGERS P.Trends in the epidemiology of focal segmental glomerulosclerosis[J].Semin Nephrol,2003,23(2):172-182.
[3] D'AGATI VD,KASKEL FJ,FALK RJ.Focal segmental glomerulosclerosis[J].N Engl J Med,2011,365(25):2398-2411.
[4] KITIYAKARA C,EGGERS P,KOPP JB.Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States[J].Am J Kidney Dis,2004,44(5):815-825.
[5] KIM YH,GOYAL M,KURNIT D,et al.Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat[J].Kidney Int,2001,60(3):957-968.
[6] MEYER T W,BENNETT P H,NELSON R G.Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type Ⅱ diabetes and microalbuminuria[J].Diabetologia,1999,42(11):1341-1344.
[7] PAGTALUNAN ME,MILLER PL,JUMPING-EAGLE S,et al.Podocyte loss and progressive glomerular injury in type Ⅱ diabetes[J].J Clin Invest,1997,99(2):342-348.
[8] WHARRAM BL,GOYAL M,WIGGINS JE,et al.Podocyte depletion causes glomerulosclerosis:diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene[J].J Am Soc Nephrol,2005,16(10):2941-2952.
[9] DAI R,LIN Y,LIU H,et al.A vital role for Angptl3 in the PAN-induced podocyte loss by affecting detachment and apoptosis in vitro[J].BMC Nephrol,2015,16:38.
[10] UDAN RS,KANGO-SINGH M,NOLO R,et al.Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway[J].Nat Cell Biol,2003,5(10):914-920.
[11] MA S,MENG Z,CHEN R,et al.The Hippo pathway:biology and pathophysiology[J].Annu Rev Biochem,2019,88:577-604.
[12] HAO Y,CHUN A,CHEUNG K,et al.Tumor suppressor LATS1 is a negative regulator of oncogene YAP[J].J Biol Chem,2008,283(9):5496-5509.
[13] ZHAO B,WEI X,LI W,et al.Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control[J].Genes Dev,2007,21(21):2747-2761.
[14] LEI Q Y,ZHANG H,ZHAO B,et al.TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway[J].Mol Cell Biol,2008,28(7):2426-2436.
[15] LIU CY,ZHA ZY,ZHOU X,et al.The Hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase[J].J Biol Chem,2010,285(48):37159-37169.
[16] ZHAO B,LI L,TUMANENG K,et al.A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)[J].Genes Dev,2010,24(1):72-85.
[17] PAVEL M,RENNA M,PARK SJ,et al.Contact inhibition controls cell survival and proliferation via YAP/TAZ-autophagy axis[J].Nat Commun,2018,9(1):2961.
[18] MARTIN AP,JACQUEMYN M,LIPECKA J,et al.STK38 kinase acts as XPO1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes[J].EMBO Rep,2019,20(11):e48150.
[19] WANG D,HE J,HUANG B,et al.Emerging role of the Hippo pathway in autophagy[J].Cell Death Dis,2020,11(10):880.
[20] ZHAO B,YE X,YU J,et al.TEAD mediates YAP-dependent gene induction and growth control[J].Genes Dev,2008,22(14):1962-1971.
[21] OUDHOFF MJ,FREEMAN SA,COUZENS AL,et al.Control of the Hippo pathway by Set7-dependent methylation of Yap[J].Dev Cell,2013,26(2):188-194.
[22] FENG X,DEGESE M S,IGLESIAS-BARTOLOME R,et al.Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry[J].Cancer Cell,2014,25(6):831-845.
[23] ZHOU X,WANG S,WANG Z,et al.Estrogen regulates Hippo signaling via GPER in breast cancer[J].J Clin Invest,2015,125(5):2123-2135.
[24] HU X,XIN Y,XIAO Y,et al.Overexpression of YAP1 is correlated with progression,metastasis and poor prognosis in patients with gastric carcinoma[J].Pathol Oncol Res,2014,20(4):805-811.
[25] REGINENSI A,SCOTT R P,GREGORIEFF A,et al.Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development[J].PLoS Genet,2013,9(3):e1003380.
[26] HOSSAIN Z,ALI SM,KO HL,et al.Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1[J].Proc Natl Acad Sci U S A,2007,104(5):1631-1636.
[27] SCHWARTZMAN M,REGINENSI A,WONG JS,et al.Podocyte-specific deletion of Yes-associated protein causes FSGS and progressive renal failure[J].J Am Soc Nephrol,2016,27(1):216-226.
[28] HUANG Z,ZHANG L,CHEN Y,et al.RhoA deficiency disrupts podocyte cytoskeleton and induces podocyte apoptosis by inhibiting YAP/dendrin signal[J].BMC Nephrol,2016,17(1):66.
[29] HUANG Z,ZHANG L,CHEN Y,et al.Cdc42 deficiency induces podocyte apoptosis by inhibiting the Nwasp/stress fibers/YAP pathway[J].Cell Death Dis,2016,7(3):e2142.
[30] ZHUANG Q,LI F,LIU J,et al.Nuclear exclusion of YAP exacerbates podocyte apoptosis and disease progression in Adriamycin-induced focal segmental glomerulosclerosis[J].Lab Invest,2021,101(2):258-270.
[31] CHEN J,CHEN M X,FOGO AB,et al.mVps34 deletion in podocytes causes glomerulosclerosis by disrupting intracellular vesicle trafficking[J].J Am Soc Nephrol,2013,24(2):198-207.
[32] CHEN J,CHEN JK,CONWAY EM,et al.Survivin mediates renal proximal tubule recovery from AKI[J].J Am Soc Nephrol,2013,24(12):2023-2033.
[33] YU FX,ZHAO B,PANUPINTHU N,et al.Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling[J].Cell,2012,150(4):780-791.
[34] BONSE J,WENNMANN DO,KREMERSKOTHEN J,et al.Nuclear YAP localization as a key regulator of podocyte function[J].Cell Death Dis,2018,9(9):850.
[35] OKU Y,NISHIYA N,SHITO T,et al.Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers[J].FEBS Open Bio,2015,5:542-549.
[36] DUPONT S,MORSUT L,ARAGONA M,et al.Role of YAP/TAZ in mechanotransduction[J].Nature,2011,474(7350):179-183.
[37] LEE VW,HARRIS DC.Adriamycin nephropathy:a model of focal segmental glomerulosclerosis[J].Nephrology (Carlton),2011,16(1):30-38.
[38] ZHAO B,LI L,LU Q,et al.Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein[J].Genes Dev,2011,25(1):51-63.
[39] 许日聪,曹陶,徐艺,等.IgA肾病肾小球节段性硬化或粘连和肾功能下降的相关性分析[J].中华肾脏病杂志,2020,36(11):851-857.

基金

国家自然科学基金面上项目（81770712）

PDF(2782 KB)

1266

Accesses

Citation

Detail

段落导航

摘要
Abstract
关键词
Key words
引用本文
参考文献
基金

收稿日期	出版日期
2022-08-20	2023-07-30
发布日期
2023-08-26

选择文件类型/文献管理软件名称

选择包含的内容

摘要

Abstract

关键词

Key words

引用本文

{{custom_sec.title}}

{{custom_sec.title}}

参考文献

{{custom_fnGroup.title_cn}}

脚注

基金

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

摘要

Abstract

关键词

Key words

引用本文

{{custom_sec.title}}

{{custom_sec.title}}

参考文献

{{custom_fnGroup.title_cn}}

脚注

基金